Breast Cancer
Conditions
Keywords
ER negative, PR negative, HER2 negative
Brief summary
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab is an antibody, which is a protein that attacks a foreign substance in the body. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors.
Detailed description
* To prepare for surgery, a small clip will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer. * The study drugs will be given in four 3-week cycles (about 3 months). Participants will come into the clinic each day they receive study treatment intravenously. Cisplatin will be given on day one of the treatment cycle (once every 3 weeks) for four cycles. Bevacizumab will be given on day one of the treatment cycle for three cycles. * On day one of each 3-week cycle a physical exam, routine blood tests and urine test will be performed. 7-8 days after chemotherapy, blood tests and a hearing test will be performed. A preoperative study visit will take place 7-10 days before surgery and a physical exam, routine blood tests, Electrocardiogram (EKG) and an Magnetic Resonance Imaging (MRI) of the breast will be performed. * Surgery to remove the tumor will occur at least three weeks after the last dose of cisplatin and is considered standard of care. * Postoperative chemotherapy will begin at least three weeks after surgery. Everyone on the research study will receive four 2-week cycles of doxorubicin and cyclophosphamide plus bevacizumab. After the 8 weeks, the doctor will decide which of the following two treatment regimens the participant will receive: Bevacizumab for four 2-week cycles (once every two weeks) or; Paclitaxel plus bevacizumab for four 2-week cycles (once every two weeks). * At the end of the postoperative chemotherapy, the participant will return to the clinic for a medical history, physical exam, vital signs, performance status, routine blood tests, multiple gated acquisition scan (MUGA) or Echocardiogram Scans, and a hearing test.
Interventions
DRUGcisplatin
Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
DRUGbevacizumab
Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
DRUGdoxorubicin
Postoperative: Given intravenously for four 2-week cycles
DRUGcyclophosphamide
Postoperative: Given intravenously for four two-week cycles
DRUGpaclitaxel
Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
Sponsors
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Genentech, Inc.
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All tumors must be ER-, PR- and HER2-negative * Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible * For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes. * 18 years of age or older * Performance status (PS) of 0 or 1 * Use of an effective means of contraception in subjects of child-bearing potential * Normal organ function as described in the protocol
Exclusion criteria
* Any prior cytotoxic chemotherapy or radiation for the current breast cancer * HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer * Life expectancy of less than 12 weeks * Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study * Renal dysfunction for which exposure to cisplatin would require dose modifications * Steroid dependent asthma * Peripheral neuropathy of any etiology that exceeds grade 1 * Uncontrolled diabetes * History of malignancy treated without curative intent * Any other pre-existing medical condition that would represent toxicity in excess of grade 1 * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive hear failure * History of myocardial infarction or unstable angina within 12 months prior to study enrollment * Any history of stroke or transient ischemic attack at any time * Known central nervous system (CNS) disease * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer or bone fracture * Proteinuria at screening * Known hypersensitivity to any component of bevacizumab * Pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer. | 2 years | The goal of this measure was to determine the pathologic complete response rate (Miller-Payne (MP) score 5) after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab | 2 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
| Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy. | 2 years | Number of patients who were unable to receive all cycles of chemotherapy on time for toxicity reasons. |
| Patients With Miller-Payne (MP) Score 3, 4, or 5 Response | 2 years | To describe a panel of molecular assays for an association with clinical response and, if feasible, with pathologic complete response (pCR) in ER-, PR-, HER2-negative subjects treated with cisplatin and bevacizumab in the preoperative setting. A Miller-Payne (MP) score of 3 indicates a decrease in the size of the cancer by 30% to 90%. A MP score of 4 indicates marked decrease in the size of the cancer by greater than 90%. A MP score of 5 indicates there is no residual cancer remaining (the same as a pathologic complete response). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cisplatin/Avastin Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
cisplatin: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
bevacizumab: Preoperatively: Given IV on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
doxorubicin: Postoperative: Given intravenously for four 2-week cycles
cyclophosphamide: Postoperative: Given intravenously for four two-week cycles
paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks) | 51 |
| Total | 51 |
Baseline characteristics
| Characteristic | Cisplatin/Avastin |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 50 Participants |
| Age, Continuous | 50 years |
| Region of Enrollment United States | 51 participants |
| Sex: Female, Male Female | 51 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 51 / 51 |
| serious Total, serious adverse events | 0 / 51 |
Outcome results
Primary
Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.
The goal of this measure was to determine the pathologic complete response rate (Miller-Payne (MP) score 5) after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer.
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin/Avastin | Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer. | 16 percentage of participants |
Secondary
Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: 2 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cisplatin/Avastin | Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab | OR = CR+PR | 39 Participants |
| Cisplatin/Avastin | Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab | CR | 12 Participants |
Secondary
Patients With Miller-Payne (MP) Score 3, 4, or 5 Response
To describe a panel of molecular assays for an association with clinical response and, if feasible, with pathologic complete response (pCR) in ER-, PR-, HER2-negative subjects treated with cisplatin and bevacizumab in the preoperative setting. A Miller-Payne (MP) score of 3 indicates a decrease in the size of the cancer by 30% to 90%. A MP score of 4 indicates marked decrease in the size of the cancer by greater than 90%. A MP score of 5 indicates there is no residual cancer remaining (the same as a pathologic complete response).
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin/Avastin | Patients With Miller-Payne (MP) Score 3, 4, or 5 Response | 45 percentage of participants |
Secondary
Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy.
Number of patients who were unable to receive all cycles of chemotherapy on time for toxicity reasons.
Time frame: 2 years
Population: analyzed the 43 patients who completed 4 cycles of neoadjuvant therapy and started post-operative treatment
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cisplatin/Avastin | Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy. | 8 Participants |